PDF Cover

Ursodeoxycholic Acid Market

The market for Ursodeoxycholic Acid was estimated at $432 million in 2024; it is anticipated to increase to $924 million by 2030, with projections indicating growth to around $1.74 billion by 2035.

Report ID:DS1802407
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Ursodeoxycholic Acid
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Ursodeoxycholic Acid Market Outlook

Revenue, 2024

$432M

Forecast, 2034

$1.53B

CAGR, 2025 - 2034

13.5%

The Ursodeoxycholic Acid industry revenue is expected to be around $490.3 million in 2025 and expected to showcase growth with 13.5% CAGR between 2025 and 2034. Building on this outlook, the ursodeoxycholic acid market continues to gain clinical and commercial importance due to its expanding role in the management of chronic liver and biliary disorders. Increasing prevalence of liver diseases, including cholestatic conditions and gallstone-related complications, is a key factor sustaining demand. Growing awareness regarding early diagnosis and treatment, along with improved access to healthcare services in emerging markets, is further strengthening market penetration. In addition, ongoing research into hepatoprotective therapies and supportive regulatory frameworks are reinforcing the relevance of ursodeoxycholic acid as a well-established and trusted therapeutic option across global healthcare systems.

Ursodeoxycholic acid is a naturally occurring bile acid widely used as a pharmaceutical agent for treating liver and gallbladder disorders. It works by reducing cholesterol absorption and improving bile flow, making it effective in dissolving certain types of gallstones and managing conditions such as primary biliary cholangitis. The drug is known for its favorable safety profile, oral administration, and long-term therapeutic benefits. It is commonly prescribed in hepatology and gastroenterology practices, with applications extending to liver transplant support and non-alcoholic fatty liver disease management. Recent trends driving demand include increasing focus on chronic liver disease management, rising adoption in combination therapies, and growing research into its broader therapeutic potential in metabolic and inflammatory conditions.

Ursodeoxycholic Acid market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Ursodeoxycholic Acid Market Outlook

Market Key Insights

  • The Ursodeoxycholic Acid market is projected to grow from $432.0 million in 2024 to $1.53 billion in 2034. This represents a CAGR of 13.5%, reflecting rising demand across Gallstone Dissolution, Liver Disease Treatment, and Cystic Fibrosis Treatment.

  • AbbVie Inc., Dr. Falk Pharma, Daewoong Pharmaceutical Co. Ltd. are among the leading players in this market, shaping its competitive landscape.

  • U.S. and China are the top markets within the Ursodeoxycholic Acid market and are expected to observe the growth CAGR of 12.2% to 16.2% between 2024 and 2030.

  • Emerging markets including Brazil, South Korea and South Africa are expected to observe highest growth with CAGR ranging between 9.4% to 14.2%.

  • Transition like Transition from niche hepatology drug to broader metabolic liver disease management therapy is expected to add $130 million to the Ursodeoxycholic Acid market growth by 2030.

  • The Ursodeoxycholic Acid market is set to add $1.1 billion between 2024 and 2034, with manufacturer targeting Hepatic Disorders & Primary Biliary Cirrhosis Application projected to gain a larger market share.

  • With

    growing prevalence of gallstone diseases, and

    Increasing Liver Disorder Treatments, Ursodeoxycholic Acid market to expand 255% between 2024 and 2034.

ursodeoxycholic acid market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Ursodeoxycholic Acid - Country Share Analysis

Opportunities in the Ursodeoxycholic Acid

The rising global burden of non alcoholic fatty liver disease is also creating a significant opportunity for ursodeoxycholic acid in hepatology care. Although not universally first line, UDCA is increasingly explored as a supportive therapy to improve liver enzyme levels and bile flow in early-stage patients. Growing clinical research and physician interest are expanding its off-label use, particularly in Asia and Europe. Oral UDCA formulations are expected to see the highest growth, driven by increasing diagnosis rates and demand for long-term, well-tolerated treatment options in metabolic liver disease management.

Growth Opportunities in North America and Asia Pacific

North America is a hub of progress in the field and supports a flourishing market for ursodeoxycholic acid due to its strong healthcare system and increased focus on liver diseases awareness driving a high demand for the medication. Multiple pharmaceutical companies take advantage of this demand in a market that prioritizes innovation. The regions research and development tax benefits and accommodating patent regulations also encourage the introduction of products, into the market. The increasing occurrence of gallstones and cholestatic liver disease in the United States and Canada has heightened the need for treatments which has become a major driving force in the market sector. In response, to this demand companies that prioritize efficiency, affordability and creativity are well positioned to discover opportunities.
In the Asia Pacific region often recognized as a growing market there is a vibrant landscape for ursodeoxycholic acid due to the rising prevalence of liver ailments in countries such as India and China driving up the need for this bile acid treatment option. As a result of this surging demand for ursodeoxycholic acid treatment solutions, in the regions pharmaceutical market sector is booming with both giants and local players vying for a share of the market creating a competitive environment where established companies face new emerging rivals. The significant role of ursodeoxycholic acid, in the treatment of gallstones and primary biliary cirrhosis contributes to market growth. Additionally the efforts of governments to promote accessible healthcare further boost this expansion.

Market Dynamics and Supply Chain

01

Driver: Rising prevalence of chronic liver diseases and increasing early diagnostic awareness globally

The growing prevalence of chronic liver diseases is also a major driver for the ursodeoxycholic acid market, particularly conditions such as primary biliary cholangitis and non alcoholic fatty liver disease. Sedentary lifestyles, alcohol consumption, and metabolic disorders are also contributing to a higher patient pool requiring long term treatment. At the same time, increasing awareness and early diagnosis of liver conditions are also significantly influencing demand. Improved screening programs and better access to diagnostic tools are also enabling earlier intervention, where ursodeoxycholic acid is also often prescribed as a first line therapy. This combination of expanding disease burden and proactive healthcare practices is also strengthening sustained demand across both developed and emerging markets.
A key driver for the ursodeoxycholic acid market is also the increasing clinical preference for safe and well tolerated oral therapies in hepatology. Physicians are also prioritizing treatments that can also be administered over long durations with minimal adverse effects, especially for chronic liver conditions. Ursodeoxycholic acid meets these requirements with its established safety profile and effectiveness in improving liver function and bile flow. This trend is also particularly evident in maintenance therapies and chronic disease management, where patient adherence is also critical. As healthcare systems focus more on long term disease control, the demand for such reliable oral medications continues to grow steadily.
02

Restraint: Intense generic competition and pricing pressures reducing profitability across global pharmaceutical markets

One of the most significant restraints in the ursodeoxycholic acid market is the rapid expansion of generic drug competition following patent expirations. This has led to substantial price erosion, particularly in mature markets where multiple low-cost alternatives are available. As a result, branded manufacturers face declining margins and reduced incentives to invest in innovation or market expansion. For example, hospitals and healthcare systems increasingly prefer cost-effective generic UDCA formulations, directly impacting premium product revenues. This shift toward price-based competition alters demand behavior, compresses profitability across the value chain, and intensifies competitive dynamics, limiting overall market value growth despite stable volume demand.
03

Opportunity: Increasing demand for pediatric liver disorder treatments in emerging healthcare markets and Growing adoption of combination therapies in advanced hepatology treatment protocols

Emerging markets are witnessing growing demand for pediatric liver disease treatments, creating new opportunities for ursodeoxycholic acid. Improved neonatal screening and rising awareness of congenital liver disorders are driving early diagnosis and treatment. UDCA is commonly prescribed in oral suspension or low-dose tablet forms for pediatric patients due to its safety profile. Countries such as India and China are expected to experience strong growth, supported by expanding healthcare infrastructure and government initiatives. Pediatric applications are likely to be a fast-growing segment as access to specialized care continues to improve.
The increasing shift toward combination therapies in hepatology is opening new avenues for ursodeoxycholic acid. Physicians are integrating UDCA with other therapeutic agents to enhance treatment outcomes in complex liver conditions such as primary biliary cholangitis and cholestatic disorders. This trend is supported by ongoing clinical research and evolving treatment guidelines that emphasize multi-drug approaches. Oral UDCA remains a core component in these regimens, with demand expected to rise in specialty care settings. This opportunity is particularly strong in developed markets where advanced treatment protocols are more widely adopted.
04

Challenge: Stringent regulatory requirements and complex manufacturing processes delaying product approvals and supply scalability

Strict regulatory frameworks and complex manufacturing requirements present another major restraint for the ursodeoxycholic acid market. Compliance with evolving global standards demands extensive clinical validation, quality assurance, and documentation, increasing development timelines and operational costs. Additionally, production relies on specialized processes and raw material sourcing, which can lead to supply disruptions and cost volatility. For instance, delays in regulatory approvals or challenges in meeting Good Manufacturing Practices can postpone product launches and restrict supply availability. These factors collectively slow market expansion, raise entry barriers for new players, and create uneven supply-demand dynamics across regions.

Supply Chain Landscape

1

Raw Material Suppliers

Sigma-Aldrich CorporationRefined Technology Co. Ltd
2

Intermediate Product Manufacturers

Mitsubishi Tanabe Pharma CorporationTeva Pharmaceuticals Industries Ltd
3

End Product Manufacturers

Daewoong Pharmaceutical Co. LtdMochida Pharmaceutical Co. Ltd
4

End Users

HealthcarePharmaceutical
Ursodeoxycholic Acid - Supply Chain

Use Cases of Ursodeoxycholic Acid in Gallstone Dissolution & Liver Disease Treatment

Gallstone Dissolution : Gallstone dissolution remains one of the most established applications of ursodeoxycholic acid, particularly in patients with cholesterol-based gallstones who are not suitable candidates for surgery. In this segment, oral pharmaceutical formulations such as tablets and capsules of Ursodeoxycholic acid are predominantly used. The therapy works by reducing cholesterol saturation in bile and gradually dissolving gallstones over time. Its non-invasive nature offers a significant advantage for patients seeking alternatives to surgical intervention. This approach is especially beneficial in early-stage cases, supporting steady demand in gastroenterology practices and outpatient care settings.
Liver Disease Treatment : In liver disease treatment, ursodeoxycholic acid is widely used for managing chronic cholestatic liver conditions, particularly primary biliary cholangitis. Standard oral formulations are prescribed for long-term therapy, as they help improve bile flow, reduce liver enzyme levels, and slow disease progression. The drug’s hepatoprotective properties and favorable safety profile make it a first-line treatment in many clinical guidelines. It is also increasingly used in conditions such as non-alcoholic fatty liver disease and drug-induced liver injury. Growing awareness of liver health and rising diagnosis rates are reinforcing its importance across hepatology and specialty care settings.
Cystic Fibrosis Treatment : Ursodeoxycholic acid is also utilized in the management of liver complications associated with cystic fibrosis, where impaired bile secretion can lead to liver damage. In this application, oral formulations are commonly administered to improve bile flow and reduce the risk of fibrosis progression. The therapy supports better liver function and helps delay severe complications in affected patients. Although this represents a relatively niche segment, increasing survival rates of cystic fibrosis patients and improved diagnosis are expanding its clinical use. Its role as a supportive therapy in multidisciplinary treatment approaches continues to drive gradual demand in specialized care environments.

Impact of Industry Transitions on the Ursodeoxycholic Acid Market

As a core segment of the Pharmaceutical industry, the Ursodeoxycholic Acid market develops in line with broader industry shifts. Over recent years, transitions such as Transition from niche hepatology drug to broader metabolic liver disease management therapy and Shift from conventional formulations to patient centric and combination therapy approaches have redefined priorities across the Pharmaceutical sector, influencing how the Ursodeoxycholic Acid market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from niche hepatology drug to broader metabolic liver disease management therapy

The ursodeoxycholic acid market is evolving from a niche treatment primarily for cholestatic liver diseases to a broader role in metabolic liver disorder management. Increasing clinical focus on conditions such as non alcoholic fatty liver disease has expanded its application scope, supported by ongoing research and off-label usage. For example, hepatologists are incorporating UDCA into early-stage treatment protocols to improve liver enzyme profiles and bile flow. This transition is increasing prescription volumes, expanding patient pools, and encouraging pharmaceutical companies to explore new indications, thereby strengthening overall market demand and long-term growth potential.
02

Shift from conventional formulations to patient centric and combination therapy approaches

Another key transition is the movement from standard oral formulations toward patient-centric delivery formats and combination therapies. Pharmaceutical companies are developing improved dosage forms such as oral suspensions for pediatric and geriatric populations to enhance compliance. At the same time, UDCA is increasingly being used alongside other drugs in combination regimens for complex liver conditions. For instance, combination therapies in primary biliary cholangitis are improving treatment outcomes and extending product usage. This shift is enhancing product differentiation, supporting lifecycle management strategies, and creating new revenue streams across diverse patient segments.